Wegovy Weight-Loss Pill Now Available at UK Pharmacies for First Time

Novo Nordisk's Wegovy semaglutide pill has gone on sale in UK high street and online pharmacies, marking its first availability in oral form.

Thousands of people in the UK have begun receiving their first doses of Wegovy in pill form, marking a significant shift in how the popular GLP-1 weight-loss medication can be accessed. Previously available only as an injectable, the once-daily oral tablet is now on sale through high street and online pharmacies across the country. The medication is made by Danish pharmaceutical company Novo Nordisk, the same manufacturer behind the injectable version of Wegovy and the diabetes drug Ozempic, both of which contain the active ingredient semaglutide. The pill format is expected to lower a practical barrier for people who were reluctant to use injectable GLP-1 medications, potentially expanding the pool of people who consider this class of treatment.

Why it matters

The oral format of a GLP-1 drug like Wegovy could meaningfully broaden access and uptake of weight-loss medication in the UK, as needle aversion has been a documented deterrent for some patients. The scale of early demand — with thousands of first deliveries already underway — signals significant public interest.

What's next

The Guardian is actively gathering reader responses on how the pill launch affects their decisions about weight-loss medication, suggesting ongoing public and media attention to uptake and outcomes.

Key facts

• Wegovy in pill form is now available at UK high street and online pharmacies
• The medication is taken once daily
• Wegovy is manufactured by Novo Nordisk, a Danish pharmaceutical company
• Thousands of people have already received first deliveries since launch
• The active ingredient, semaglutide, is the same used in injectable Wegovy and Ozempic
• The pill format is new — Wegovy was previously only available as an injection

Bias & framing notes

Both sources are from The Guardian, limiting editorial diversity. The second source provides concrete reporting on the launch itself, while the first is a reader callout that adds no independent factual detail. Key specifics — such as pricing, prescription requirements, and NHS versus private availability — are absent from the available reporting, leaving an incomplete picture of access conditions.